These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1989248)

  • 21. Portal capillary destruction in liver allograft rejection.
    Matsumoto Y; McCaughan GW; Bishop GA
    Transplant Proc; 1992 Feb; 24(1):196-7. PubMed ID: 1539242
    [No Abstract]   [Full Text] [Related]  

  • 22. Diagnosis and grading of liver allograft rejection: a European perspective.
    Hübscher S
    Transplant Proc; 1996 Feb; 28(1):504-7. PubMed ID: 8644330
    [No Abstract]   [Full Text] [Related]  

  • 23. Significance of central perivenulitis in pediatric liver transplantation.
    Abraham SC; Freese DK; Ishitani MB; Krasinskas AM; Wu TT
    Am J Surg Pathol; 2008 Oct; 32(10):1479-88. PubMed ID: 18708942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FK 506 rescue therapy: early conversion improves efficacy.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent cytomegalovirus in liver allografts with chronic rejection.
    Lautenschlager I; Höckerstedt K; Jalanko H; Loginov R; Salmela K; Taskinen E; Ahonen J
    Hepatology; 1997 Jan; 25(1):190-4. PubMed ID: 8985289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection.
    Matsumoto Y; McCaughan GW; Painter DM; Bishop GA
    Transplantation; 1993 Jul; 56(1):69-75. PubMed ID: 8333070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection.
    Sandborn WJ; Hay JE; Porayko MK; Gores GJ; Steers JL; Krom RA; Wiesner RH
    Hepatology; 1994 Apr; 19(4):925-32. PubMed ID: 8138267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract]   [Full Text] [Related]  

  • 30. The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us?
    Demetris AJ; Murase N; Delaney CP; Woan M; Fung JJ; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):67-70. PubMed ID: 7879139
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of cyclosporine A in combination with low-dose corticosteroids and azathioprine in liver transplantation.
    Gugenheim J; Samuel D; Saliba F; Castaing D; Bismuth H
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):366-8. PubMed ID: 3291269
    [No Abstract]   [Full Text] [Related]  

  • 32. Vanishing bile-duct syndrome following liver transplantation--is it reversible?
    Hubscher SG; Buckels JA; Elias E; McMaster P; Neuberger J
    Transplantation; 1991 May; 51(5):1004-10. PubMed ID: 1851580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporine A monitoring in liver transplant.
    Tisone G; Vennarecci G; Pisani F; Pieragostini E; Alciati E; Casciani CU
    Transplant Proc; 1994 Oct; 26(5):2691-2. PubMed ID: 7940842
    [No Abstract]   [Full Text] [Related]  

  • 34. [Rejection of a liver allograft. Diagnosis and treatment].
    Calmus Y
    Ann Radiol (Paris); 1994; 37(5):377-82. PubMed ID: 7527621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppression in liver transplantation.
    Post DJ; Douglas DD; Mulligan DC
    Liver Transpl; 2005 Nov; 11(11):1307-14. PubMed ID: 16237688
    [No Abstract]   [Full Text] [Related]  

  • 36. Increased bile duct complications in ABO incompatible liver transplant recipients.
    Sanchez-Urdazpal L; Sterioff S; Janes C; Schwerman L; Rosen C; Krom RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1440-1. PubMed ID: 1989259
    [No Abstract]   [Full Text] [Related]  

  • 37. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy.
    Neuhaus B; Keck H; Bechstein WO; Blumhardt G; Langrehr JM; Wiens M; Lemmens HP; Lohmann R; Schlag H; Thalmann U
    Transplant Proc; 1993 Feb; 25(1 Pt 1):587-9. PubMed ID: 8438426
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
    Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of transplant rejection in the presence of cytomegalovirus viremia.
    O'Hair DP; Johnson CP; Roza AM; Adams MB
    Transplant Proc; 1990 Aug; 22(4):1815-7. PubMed ID: 2167537
    [No Abstract]   [Full Text] [Related]  

  • 40. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
    Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
    Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.